Savolitinib is under clinical development by Hutchison MediPharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Savolitinib’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Savolitinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Savolitinib overview

Savolitinib (Orpathys) is a potent antineoplastic agent. It is formulated as tablets for the oral route of administration. Orpathys is indicated for the treatment of patients with non-small cell lung cancer who have progressed following prior systemic therapy or are unable to receive chemotherapy.

Savolitinib (AZD-6094) is under development for the treatment of gastric cancer, adenocarcinoma of the gastroesophageal junction, papillary, metastatic castration-resistant prostate cancer, non-small cell lung cancer, advanced or metastatic pulmonary sarcomatoid carcinoma, metastatic colorectal cancer. The drug candidate is administered orally. Volitinib acts by targeting ATP-competitive c-Met receptor.

It was also under development for primary CNS tumors including medulloblastoma, high-grade glioma and diffuse intrinsic pontine glioma, solid tumors, clear cell renal cell carcinoma, breast cancer and hepatocellular carcinoma

Hutchison MediPharma overview

Hutchison MediPharma (HMPL) carries out discovery, development and commercialization of therapeutics in oncology and autoimmune diseases. The company’s products include savolitinib, fruquintinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. It develops drug discovery technologies in molecular and cell biology, high throughput screening, genomics and informatics to support research and development projects. HMPL’s research and development programs comprise gene-targeted and cell-based screening assays, ligand-dependent screening assays and signal transduction pathway screening assays. The company’s products serve in the fields of medicinal chemistry, pharmacology, oncology, cardiovascular and respiratory diseases, and antiviral treatments. It operates through its two offices in Pudong, China. HMPL is headquartered in Pudong, China.

Quick View Savolitinib LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Savolitinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.